Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

Recs

1
Player Avatar wtcrane1 (97.50) Submitted: 10/14/2010 10:51:28 AM : Outperform Start Price: $13.23 ALNY Score: -36.54

cutting edge technology and patents

Featured Broker Partners


Advertisement